The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-α ex vivo

Journal of Clinical Pharmacology

Volumn 42, Issue 3, 2002, Pages 297-303

  Wurst, Wilhelm ^a   Hatzelmann, Armin ^a   Neuhauser, Markus ^a   Timmer, Wolfgang ^a  

^a ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; LIPOPOLYSACCHARIDE; PLACEBO; ROFLUMILAST; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE RELEASE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE INDUCED ASTHMA; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INFLAMMATORY CELL; LUNG FUNCTION; MALE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; TREATMENT OUTCOME;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADULT; AMINOPYRIDINES; ANALYSIS OF VARIANCE; ASTHMA, EXERCISE-INDUCED; BENZAMIDES; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; CYCLOPROPANES; DOUBLE-BLIND METHOD; HUMANS; LIPOPOLYSACCHARIDES; MALE; PHOSPHODIESTERASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036179542     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700222011328     Document Type: Article

References (21)

1. Therapeutic potential of selective PDE inhibitors in asthma
2. Theophylline and isoenzyme-selective phosphodiesterase inhibitors
3. Phosphodiesterase isozymes: Molecular targets for novel antiasthmatic agents
4. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD)
5. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation
6. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro
7. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor
8. High oral absolute bioavailability or roflumilast, a new, orally active, once daily PDE4 inhibitor
9. Sample size estimation in studies monitoring exercise-induced bronchoconstriction in asthmatic children
10. Nonallergic airway hyperresponsiveness
11. PDE isoenzymes as targets for anti-asthma drugs
12. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD
13. Phosphodiesterase 4 inhibitors and the treatment of asthma
14. Differential regulation of human monocyte-derived TNF-α and IL-1β by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors
15. Suppression of anti-CD3-induced interleukin-4 and interleukin-5 release from splenocytes of Mesocestoides Corti-infected BALB/c mice by phosphodiesterase 4 inhibitors
16. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: Synergism with prostanoids and salbutamol
17. Phosphodiesterase, 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leucocytes
18. Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma
19. Exercise-induced asthma: The state of the art
20. Summary of clinical trials with zafirlukast
21. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist